

## **Disclosure of Value Transfers**

## **Methodological Note**

Country	Lithuania, Estonia, Latvia
Entity Name	Fresenius Kabi Baltics UAB
Legal Basis for Disclosure	- <b>Lithuania:</b> Code of Ethics for Pharmaceutical Marketing. 2020 edition. Adopted by IFPA on 18/06/2020, VGA on 25/06/2020.
	Order of the Ministry of Health no. V-1537, 23/06/2020;
	<ul> <li>Estonia: Medicinal Products Act. 2005 edition. Clause 83.</li> <li>General requirements for advertising of medicinal products;</li> </ul>
	- Latvia: Cabinet rules nr. 378, adopted on 17/05/2011.
Reporting Period	2020
Currency of disclosed values	All values are disclosed in  ☑ EUR
	□ [local currency, if required]
Scope of disclosure	The disclosure covers all interactions with HCPs, HCOs and Patient Organizations medicines related to all prescription-only medicinal products (generic, original or biosimilar). Interactions related to medical devices or enteral nutrition products are not disclosed.
Value identification and Recognition	All values disclosed are based on value transfers actually made the respective category that such value transfer has been made to a specific recipient as booked in the respective reporting period (educational grants are disclosed based on the reporting period of the event/congress).
Multi-Year Contracts	Value transfers under multiyear contracts are part of the disclosed data to the extent that actual value transfers have been made in the respective reporting period.
Data disclosed	All values are disclosed for
for	□ Recipients which have been engaged by entity (e.g. Medicines for Europe)
	☐ Recipients which have their residence in the country (e.g. EFPIA)
VAT and other taxes	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction, except for Company Organised Meetings/Site Visits, which are disclosed VAT excluded.

Annex Document No.: Version: Date of Publication:

00

Date: Page:

1 of 2

2021-06-30



## **Disclosure of Value Transfers**

Disclosure location:	<ul> <li>Lithuania, Estonia (MfE disclosure): <a href="https://www.fresenius-kabi.com/company/transparency-initiative">https://www.fresenius-kabi.com/company/transparency-initiative</a></li> </ul>
	- Lithuania (State Agency of Medicines):
	https://www.vvkt.lt/index.php?3523782702
	- Latvia (State Agency of Medicines):
	https://www.vi.gov.lv/lv/pazinojums-par-biedribam-
	nodibinajumiem-un-arstniecibas-iestadem-sniegto-materialo-
	vai-cita-veida-atbalstu-0

Other Remarks	For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained.
	Fees paid in connection with research & development activities or market research have not been disclosed.

Annex Document No.: Date: 2021-06-30 Version: Date: 2 of 2

Date of Publication: